Actively Recruiting
Observational Study on Abrocitinib Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis Unresponsive to Previous Biologic Treatments
Led by Pfizer · Updated on 2026-08-17
150
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective, multi-center observational study to understand the clinical and patient-reported outcomes of patients with moderate-to-severe atopic dermatitis who have not responded well or are intolerant to two or more previous biologic therapies. This study focuses on patients receiving abrocitinib, aiming to assess its effectiveness in a real-world setting for those with limited treatment options. Participants in the study are patients taking abrocitinib for moderate-to-severe atopic dermatitis. The study collects observational data without altering treatment, following patients who have been prescribed abrocitinib according to usual clinical practice. The study will monitor patients over time to assess outcomes related to skin improvement, itch reduction, and patient satisfaction among others. Throughout the study, participants will be observed and asked to complete patient-reported outcome questionnaires and other assessments regularly. Researchers will measure various outcomes such as the percentage of patients achieving significant improvement in skin symptoms and itch, changes in sleep quality, and overall satisfaction with treatment. Data collection will include clinical evaluations and patient diaries to track progress for up to 16 weeks after starting abrocitinib.
CONDITIONS
Brief Title
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here